EMI 400
Alternative Names: EMI-400Latest Information Update: 28 Mar 2021
Price :
$50 *
At a glance
- Originator Edinburgh Molecular Imaging
- Class Diagnostic agents
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary fibrosis
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Pulmonary-fibrosis(Diagnosis) in United Kingdom (Parenteral)
- 16 Feb 2017 Preclinical trials in Pulmonary fibrosis (Diagnosis) in United Kingdom (Parenteral) before February 2017 (Edinburgh Molecular Imaging pipeline, February 2017)